文献速递类风湿关节炎

依那西普治疗幼年特发性关节炎:无活动性疾病与缓解的预测因素

Predictors of inactive disease and remission in children and young adults with juvenile idiopathic arthritis treated with etanercept.
PubMed 文献 · Rheumatology (Oxford) · 2026-01-01

基于CLIPPER/CLIPPER2研究,分析依那西普治疗的幼年特发性关节炎患者中临床无活动性疾病(CID)和临床缓解(CR)的预测因素。约三分之二患者达到CID,34-43%达到CR;早期治疗反应(3个月JADAS低疾病活动度)、较小发病年龄、HLA-B27阳性及基线低疾病活动度与CID和CR相关。

要点

  • 3个月时JADAS低疾病活动度是CID和CR的预测因素。
  • 发病年龄≤12岁、HLA-B27阳性与JADAS定义的CID相关。
  • 身高Z评分≥0.74和正常CRP水平预测JADAS CID。

核心结论

  • 依那西普治疗的JIA患者中,早期治疗反应、较小年龄、HLA-B27阳性及基线低疾病活动度与CID和CR相关。

研究设计与样本

  • 基于3b期开放标签CLIPPER研究(NCT00962741)及其8年延伸研究CLIPPER2(NCT01421069),纳入扩展型少关节炎(2-17岁)、附着点炎相关关节炎或银屑病关节炎(各12-17岁)患者,采用多变量逐步逻辑回归模型识别预测因素。

主要发现

  • 约三分之二患者在任一时刻达到CID标准,34-43%达到CR。
  • 身高Z评分≥0.74、发病年龄≤12岁、正常CRP水平、HLA-B27阳性、3个月时JADAS低疾病活动度及≤4个肿胀关节预测JADAS CID。
  • BMI Z评分>0.80、发病年龄≤12岁、正常CRP水平及3个月时JADAS低疾病活动度预测JIA-ACR CID。
  • 3个月时JADAS低疾病活动度预测JADAS CR;身高Z评分>1.23、3个月时JADAS低疾病活动度及>12个肿胀关节预测JIA-ACR CR。

关键数值与推荐

  • CID根据幼年关节炎疾病活动评分(JADAS)和JIA-ACR反应标准定义;CR定义为CID持续≥6个月。

临床怎么用

  • 对依那西普治疗的JIA患者,应关注3个月时的JADAS低疾病活动度以实现达标治疗,并考虑发病年龄、HLA-B27状态及基线疾病活动度。

局限性

  • 原文未报告

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To identify predictors of clinically inactive disease (CID) and clinical remission (CR) in patients with juvenile idiopathic arthritis receiving etanercept during the 2-year, phase 3b, open-label CLIPPER study (NCT00962741) and the 8-year extension study, CLIPPER2 (NCT01421069). METHODS: Patients with extended oligoarthritis (2-17 years), enthesitis-related arthritis or psoriatic arthritis (each 12-17 years) were enrolled in CLIPPER/CLIPPER2. Predictors of CID (according to Juvenile Arthritis Disease Activity Score [JADAS] and JIA-ACR response criteria) and CR (≥6 months of CID) were identified using a multivariate stepwise logistic regression model. RESULTS: Two-thirds of patients met the criteria for CID at any point and 34-43% achieved CR. Height Z-score ≥0.74, age at onset ≤12 years, normal CRP levels, HLA-B27+ status, JADAS low disease activity (LDA) at 3 months and ≤4 swollen joints were predictive of JADAS CID. BMI Z-score >0.80, age at onset ≤12 years, normal CRP levels and JADAS LDA at 3 months were predictors of JIA-ACR CID. JADAS LDA at 3 months was a predictor of JADAS CR, and height Z-score >1.23, JADAS LDA at 3 months and >12 swollen joints were identified as predictors of JIA-ACR CR. CONCLUSION: In patients with JIA treated with etanercept, early responses to treatment in line with treat-to-target recommendations, younger age, HLA-B27+ status and lower disease activity at baseline were associated with clinically inactive disease and clinical remission. TRIAL REGISTRATION: ClinicalTrials.gov IDs: CLIPPER (NCT00962741); CLIPPER2 (NCT01421069).

来源:Rheumatology (Oxford),查看原文。版权归原作者所有。

引用

  1. Chasnyk V, Constantin T, Nikishina I, et al. Predictors of inactive disease and remission in children and young adults with juvenile idiopathic arthritis treated with etanercept. Rheumatology (Oxford). 2026. PMID: 42011511. doi:10.1093/rheumatology/keag198

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。